Answers are grounded in this paper and cite their sources.
Case report highlights ctDNA monitoring to optimize olaparib treatment for early-stage breast cancer patients with BRCA2 mutations.
This report underscores the potential benefit of olaparib for early-stage TNBC patients with somatic BRCA2 mutations and the utility of serial ctDNA monitoring for tailoring individualized treatment strategies.
No takes yet. Share an insight, caveat, or question.
You et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: